Business Results
Fiscal Year Ended March 31, 2016
Hisashi Ietsugu,
Chairman and CEO
May 12, 2016
Contents
Chapter 1 Financial Highlights for the
Fiscal Year Ended March 31, 2016
Chapter 2 Consolidated Earnings Forecast for the
Fiscal Year Ending March 31, 2017
Forward-Looking Statements
This material contains forward-looking statements about Sysmex Corporation and its Group companies (the Sysmex
Group). These forward-looking statements are based on the current judgments and assumptions of the Sysmex Group in
light of the information currently available to it. Uncertainties inherent in such judgments and assumptions, the future
course of our business operations and changes in operating environments both in Japan and overseas may cause our
actual results, performance, achievements, or financial position to be materially different from any future results,
performance, achievements or financial position either expressed or implied within these forward-looking statements.
Chapter 1
Financial Highlights for the Fiscal Year Ended March 31, 2016
Financial Highlights
Net sales: Up for 16 consecutive fiscal years
Operating income: Up for 15 consecutive fiscal years
Net sales and all income categories reached historic highs
(Billions of yen)
253.1
(Billions of yen)
221.3
45.9
184.5
Fiscal year ended
March 31, 2016
56.9
Results
54.3
Net Sales
Cost of Sales
134.7
145.5
33.7
44.4
SG&A
36.2
22.9
32.8
19.2
19.1
12.0
Operating Income
26.6
21.8
Ordinary Income
20.5
Net Income
14.1


2012
2013
2014
2015
2016
(Fiscal years ended March 31)
Net Sales
Operating Income
Ordinary Income
Profit Attributable to Owners of Parent
Fiscal year ended Fiscal year ended
March 31, 2016
March 31, 2015
1USD
¥120.1
¥109.9
1EUR
¥132.6
¥138.8
1CNY
¥18.9
¥17.8


Ratio
253.1 100%
Fiscal year ended
March 31, 2015
Results
YOY (Previous
period = 100%)
Ratio
221.3
100%
114.4%
102.0
40.3%
95.3
43.1%
107.0%
94.1
37.2%
81.6
36.9%
115.3%
56.9
54.3
36.2
22.5%
44.4
20.1%
128.3%
21.5%
45.9
20.8%
118.3%
14.3%
26.6
12.0%
136.0%
Net sales:
The Company recorded sales growth in all overseas
geographic regions, centered on China.
Operating income:
Operating income rose substantially thanks to the effects of
higher sales and yen depreciation (against the U.S. dollar and
the Chinese yuan).
Non-operating balance:The forex loss was ¥2.74 billion (¥0.93 billion gain in the
previous fiscal year).
Extraordinary income: Extraordinary income amounted to ¥0.31 billion (¥0.22 billion
extraordinary loss in the previous fiscal year).
Notes: Exchange rate fluctuations raised net sales ¥3.22 billion and operating income ¥8.54 billion.
At the exchange rates prevailing one year earlier, net sales would have been up 12.9% year on
year, and operating income up 9.0%.

Capital expenditure (tangible): ¥13.09 billion
Depreciation and amortization: ¥12.25 billion R&D expenditure: ¥17.77 billion
3/25
Breakdown of Net Sales and Operating Income
(Billions of yen)
Operating Income
Net Sales
Gross profit decreased as a
result of a worsening cost of
sales ratio (excluding FX impact)
Note: FX impact excluded from regional sales below
FX impact
2.5
12.1
7.7
3.2
Gross profit on
increased sales
AP
16.2
China
(0.2)
SG&A expense
increase
FX impact
(11.9)
8.5
6.7 EMEA
Americas
Japan
(0.7)
¥12.5 billion
¥31.7 billion
2015
(Fiscal years ended March 31)
2015
2016
4/25
(Fiscal years ended March 31)
2016
Breakdown of Assets and Liabilities/Net Assets
(Billions of yen)
Liabilities/Net Assets
Assets
Noncurrent assets
Current assets
Up ¥1.13 billion
Up ¥18.51 billion
Intangible
noncurrent assets
(0.5)
Other current assets
2.1
Net assets
Liabilities
Up ¥18.54 billion
Up ¥1.11 billion
Other
noncurrent
assets
(0.4)
Retained Other net
earnings assets
(7.3)
9.7
Cash and
deposits
Property,
plant and
equipment
25.8
2.4
Current
liabilities
6.2
0.7
Notes/accounts
receivable
Noncurrent
liabilities
Up ¥19.6 billion
Up ¥19.6 billion
2015
(Fiscal years ended March 31)
0.3
2015
2016
5/25
(Fiscal years ended March 31)
2016
Consolidated Cash Flows
(Billions of yen)
Operating CF
38.6 39.5
36.5
Investing CF
Financing CF
Increase/decrease in
“cash and cash
equivalents”*
13.6
6.8
2.2
‐2.8
‐7.5
‐8.7
‐19.5 ‐21.6
‐33.9
2014
2015
2016
(Fiscal years ended March 31)
*Includes translation differences on cash and cash equivalents.
6/25
Topics
M&A, Alliances
 Sysmex enters business alliance agreement with EIKEN CHEMICAL CO., LTD., involving the
urine chemistry testing business in overseas markets (January 2016)
 Sysmex and Siemens extend long-standing global partnership in hemostasis testing (April 2016)
 Sysmex enters strategic collaboration with leading U.S. commercial lab, LabCorp, for bloodbased molecular testing services and products to support the development of precision medicine
in oncology (June 2015)
Operational Sites
 Sysmex completes expansion of reagent factory in Germany, increasing reagent production
capacity by 50% (July 2015)
 Sysmex expanding U.S. reagent factory to meet growing demand in the Americas (Scheduled for
completion in June 2017)
 Sysmex establishes new subsidiary in Ghana, reinforcing the Company’s business foundation in
the markets of West and Central Africa (October 2015)
 Sysmex opens new R&D Open Innovation Lab within Technopark
(October 2015)
Subsidiary in Ghana
7/25
Topics
Products, Technologies
 Sysmex launches its next-generation models in the sediment urinalysis testing field, the
UF-5000/4000/3000 fully automated analyzers of formed elements in urine (September
2015)
 Sysmex launches the UC-3500 fully automated urine chemistry analyzer, its first product
in the field of urine qualitative analysis in overseas markets (January 2016)
 Sysmex launches a new product in the sediment urinalysis testing field, the UD-10 fully
automated imaging unit for formed elements in urine (January 2016)
 New liquid biopsy RAS testing for metastatic colorectal cancer patients has been
granted CE Mark approval (April 2016)
Urinalysis
transport
system
Others
 Sysmex selected as one of the 2016 Global 100’s Most Sustainable Companies in the
World (January 2016)
 Sysmex selected by the Securities Analysts Association of Japan for “Excellence in
Corporate Disclosure” and “Excellence in Disclosure to Individual Investors,” and wins
the “IR Grand Prix Award” from Japan Investor Relations Association (October and
November 2015)
8/25
Net Sales by Geographic Region
(Billions of yen)
Net Sales by Geographic Region (Sales to Customers)
Fiscal year ended
March 31, 2016
Fiscal year ended
March 31, 2015
Results Ratio
Results Ratio
253.1 100%
Americas
YOY
(Previous period = 100%)
(Yen)
(Local currency)
221.3 100%
114.4%
-
56.4 22.3%
47.0 21.2%
120.1%
109.9%
EMEA
68.4 27.0%
63.2 28.6%
108.2%
113.3%
Region China
65.1 25.7%
49.8 22.5%
130.7%
123.3%
AP
20.0
17.8
8.1%
112.3%
-
Japan*
43.0 17.0%
43.3 19.6%
99.1%
-
Net Sales
7.9%
* Includes sales to IDEXX and other customers
 Percentage of Sales in Emerging Markets
Fiscal year ended
March 31, 2015
Exchange Rates
Fiscal year ended Fiscal year ended
March 31, 2016
March 31, 2015
1USD
¥120.1
¥109.9
1EUR
¥132.6
¥138.8
1CNY
¥18.9
¥17.8
9/25
36.1%
Net sales:
¥221.3 billion
Fiscal year ended
March 31, 2016
38.9%
Net sales:
¥253.1 billion
Sales by Business
(Billions of yen)
Year ended March 31, 2016
Year ended March 31, 2015
Results
Ratio
159.7
63.1%
17.5
6.9%
177.2
70.0%
Immunochemistry
7.7
3.1%
4.7
2.1%
164.1%
Clinical Chemistry
3.5
1.4%
3.7
1.7%
96.6%
44.1
17.4%
33.6 15.2%
131.2%
55.5
21.9%
42.1 19.0%
131.9%
LS-BU
3.3
1.3%
3.1
1.4%
107.8%
*
17.0
6.7%
18.7
8.5%
90.8%
253.1
100.0%
221.3 100.0%
114.4%
Hematology
Urinalysis
HU-BU
Hemostasis
ICH-BU
Others
Total Net Sales
Results
Ratio
YOY (Previous
= 100% )
140.9 63.7%
16.4
113.3%
7.4%
106.7%
157.3 71.1%
112.6%
* Clinical laboratory information systems, sales of third-party products, FCM products for research and industry, simple
FCM products for emerging markets, etc.
Simple FCM products for emerging markets, formerly included in “Others” in HU-BU, have been reclassified as
“Others.”
10/25
Geographic Segment Information: Americas
56.4 （単位：億円）
Billions of yen
47.0 (Billions of yen)
38.5 29.7 26.8 2.8 *
2012
2.1 *
2013
Net Sales
2.4 *
2014
2.4 *
2015
Million USD
36.3
*
2.0
2.4
120.1% 109.9%
86.7%
79.4%
2016
Notes: Excluding the impact of the reversal in deferred service revenue and income in the first three months of the fiscal year
ended March 31, 2015, net sales would have been up 21.2% and operating income up 2.0%.
(The reversal in deferred service revenue and income in the first three months of the fiscal year ended March 31, 2015,
had a ¥0.42 billion positive impact on net sales and a ¥0.36 billion positive impact on operating income.)
The abolition of an excise tax in the fourth quarter of the fiscal year ended March 31, 2016, had a ¥0.14 billion positive
impact on operating income.
470.1 
385.0 
Net sales rose substantially, as service activities generating high levels of
customer satisfaction and the competitiveness of the XN-Series led to
higher sales of instruments, reagents and services.
Operating income decreased due to a reversal in deferred service revenue
and income in the fiscal year ended March 31, 2015, and a rise in SG&A
expenses to strengthen sales and after-sales service activities in the
United States.
Local Currency Basis
25.6
*
24.7
*
21.8
*
•
17.3
*
2012
47.0
2.0 *
427.7 357.4 56.4
Operating Income*
(Fiscal years ended March 31)
Operating Income
Net Sales
339.6 YOY
Fiscal year
Fiscal year
(Previous
period = 100%)
ended
ended
(Yen basis) (Local currency
March 31, 2016 March 31, 2015
basis)
2013
2014
2015
2016
(Fiscal years ended March 31)
Operating Income
Net Sales
•
United States:
Sales grew due to higher sales of system products,
stemming from the acquisition of large-scale projects
in the hematology field.
Central and South America: Sales rose slightly, as the acquisition of a large-scale
government project in Mexico overcame the impact of
depreciation in the value of the real.
*Revision in intragroup transaction prices
11/25
Geographic Segment Information: EMEA*
68.4 *Europe, the Middle East and Africa
63.2 (Billions of yen)
Billions of yen
53.1 39.4 37.0 Net Sales
68.4
63.2
108.2%
113.3%
2.7
5.1
53.2%
55.7%
8.6 Operating Income*
5.7 5.3
2012
2013
5.1
*
2014
2015
2.7 *
2016
(Fiscal years ended March 31)
Net Sales
Operating Income
516.3 455.8 Million EUR
YOY
Fiscal year
Fiscal year
(Previous
period = 100%)
ended
ended
(Yen basis) (Local currency
March 31, 2016 March 31, 2015
basis)
339.8 49.4 368.0 54.1 395.9 2013

Operating income fell despite the increase in net sales because of the
revision in intragroup transaction prices and increased operating
expenses at Partec and Inostics.
Note: Absent the impact of Partec and Inostics, net sales would have been up 10.5%, and operating
income down 13.7%.
• Five major countries:
64.0 Large-scale projects in Italy and Spain pushed up sales.
• Other parts of Europe:
2014
2015
20.9 *
2016
(Fiscal years ended March 31)
Net Sales
Net sales increased throughout the region—in the Middle East, Russia
and other emerging markets, as well as the five major countries.
Local Currency Basis
37.5 **
2012

Sales increased in Denmark due to the acquisition of
major projects, as well as in other countries.
• Eastern Europe, Russia: Sales increased thanks to expansion in the hematology
field in Poland, and in Russia due to the acquisition of a
project for a large-scale commercial lab.
• Middle East, Africa:
Operating Income
*Revision in intragroup transaction prices
12/25
Sales increased thanks to the winning of a tender offer for
facilities in Saudi Arabia operated by the country’s Ministry
of Health.
Geographic Segment Information: China
65.1 Billions of yen
（単位：億円）
(Billions of yen)
49.8 Net Sales
36.2 6.8
24.4 19.2 2.3
2.3
*
*
2012
2013
YOY
Fiscal year
Fiscal year
(Previous
period = 100%)
ended
ended
(Yen basis) (Local currency
March 31, 2016 March 31, 2015
basis)
5.5
*
*
4.1
*
2014
2015
Operating Income*
3,455.9 49.8
130.7%
123.3%
5.5
6.8
81.8%
77.1%

Sales in the hematology, hemostasis and immunochemistry fields
pushed up net sales substantially.

Operating income was down year on year due to impact of the revision
in intragroup transaction prices and higher SG&A expenses to
reinforce activities in the immunochemistry field.
2016
(Fiscal years ended March 31)
Net Sales
Operating Income
65.1
Million CNY
2,803.1 Local Currency Basis
2,223.1 1,851.8 1,561.4 • Hematology:
382.6
295.1
*
257.2
*
191.7 180.7
*
*
*
2012
2013
2014
2015
2016
(Fiscal years ended March 31)
Net Sales
Operating Income
•
•
•
Sales were up year on year, reflecting robust sales of
instruments in the XN-Series for system proposals.
Hemostasis:
Sales of instruments and reagents grew significantly due
to strong sales of the high-end CS-Series and increased
demand for fibrin parameter reagents.
Urinalysis:
Sales were flat, due in part to the effect of a period of
transition to new products.
Immunochemistry: Sales increased due to expanded sales of the
HISCL-Series (commencing in the third quarter of the
fiscal year ended March 31, 2015).
*Revision in intragroup transaction prices
13/25
Geographic Segment Information: AP
（単位：億円）
Billions
of yen
(Billions of yen)
20.0 17.8 Operating Income*
*
1.3 1.0 *
2014
*
2015
1.8
1.2
147.3%

Operating income increased, reflecting higher sales.
•
Southeast Asia:
Sales increased, centered on higher sales in the
hematology field in Indonesia, Vietnam and the Philippines.
•
South Asia:
•
Oceania:
In addition to sales growth in the hematology and clinical
chemistry fields in India, successful efforts against other
companies boosted sales in the hematology field in
Bangladesh.
Sales were up slightly, reflecting the acquisition of largescale projects in Australia, as in the previous year.
•
South Korea, Taiwan: Sales were up due to increased sales in South Korea,
centering on hematology instruments and reagents.
2016
(Fiscal years ended March 31)
Net Sales
112.3%
Net sales for the region increased, with higher sales centered on the
hematology field in India, Indonesia and South Korea.
0.3 2013
17.8
1.2 *
*
2012
20.0

1.8 9.0 YOY (Previous
period = 100%)
(Yen basis)
Net Sales
14.7 7.8 Fiscal year ended Fiscal year ended
March 31, 2016 March 31, 2015
Operating Income
*Revision in intragroup transaction prices
14/25
Geographic Segment Information: Japan
Billions of yen
144.0 (Billions of yen)
Net Sales
Fiscal year ended
March 31, 2016
Fiscal year ended
March 31, 2015
YOY
(Previous period =
100%)
144.0
122.9
117.2%
43.0
43.3
99.1%
39.8
40.5
98.2%
3.1
2.8
111.3%
101.0
79.5
127.0%
41.7
31.1
134.1%
122.9 101.0 *
Sales to Customers
103.8 79.5 82.7 39.0 Japan
41.7
88.1 62.0 *
IDEXX and
Others
31.1
45.1 Intra-Area Transfers
*
Operating Income*
20.1
3.9
2.7
*
*
11.9
1.4
2.8
3.1
8.6
39.7
2012
40.1
40.3
40.5
39.8
2013
2014
2015
2016
 Net sales and operating income were up, despite a slight
decline in the Japanese market, as intra-area transfers to Group
affiliates (overseas) pushed up internal sales, and the region
benefited from the impact of a revision in intragroup
transaction prices.
(Fiscal years ended March 31)
Intra-Area Transfers: Exports to Group Affiliates, Others
Sales to Customers: IDEXX and Others
Sales to Customers: Japan
Operating Income
*Revision in intragroup transaction prices
• Japan:
Lower instrument sales led to a slight decrease in sales
in the region, despite increased reagent sales centered
on the immunochemistry field.
• IDEXX and others: Sales were up, thanks to robust sales of instruments
for IDEXX.
15/25
Dividend Forecast
Proposal corresponds to a payout ratio
of 36.8% and the 14th consecutive year
of increases
Expected dividend ¥12 higher than initial year-end dividend forecast
of ¥40 (a ¥4 higher interim dividend and ¥8 higher year-end dividend)
Fiscal Year Ended
March 31, 2015
Fiscal Year Ended
March 31, 2016
(Proposal)
Interim
Dividend
Year-End
Dividend
Total
Payout
Ratio
¥16
¥22
¥38
29.6%
¥24
¥28
¥52
29.8%
Note: Includes dividend
commemorating the
Company’s 20th
anniversary of listing
(¥4)
Note: To be proposed
at the 49th Ordinary
General Meeting of
Shareholders
16/25
Chapter 2
Consolidated Earnings Forecast for the
Fiscal Year Ending March 31, 2017
Consolidated Earnings Forecast
Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2017, IFRS Standards
(Figures in parentheses are based on Japanese accounting standards.)
Net Sales: ¥275.0 billion
Operating Income: ¥62.0 billion
(¥61.0 billion)
Operating Margin: 22.5%
(22.2%)
Profit Attributable to Owners of Parent:
¥40.5 billion
(¥39.5 billion)
Profit Attributable to Owners of Parent to Net Sales: 14.7%
(14.4%)
Planned Investment
Capital Expenditure: ¥10.0 billion Depreciation and Amortization: ¥14.2 billion
IFRS Standards
Assumed exchange Actual for fiscal year
rates for full year ended March 31, 2016
1USD
¥110.0
¥120.1
1EUR
¥125.0
¥132.6
1CNY
¥17.0
¥18.9
(Billions of yen)
¥0.53 billion
¥0.42 billion
¥4.36 billion
¥0.58 billion
¥0.21 billion
¥0.32 billion
(Up 8.6%)
253.1 221.3 184.5 33.7 Net Sales
Operating Income
Ordinary Income
275.0 275.0 Exchange rate sensitivity Exchange rate sensitivity
of net sales
of operating income
(year)
(year)
USD
EUR
CNY
R&D Expenditure: ¥16.2 billion
32.8 20.5 2014
Profit Attributable to
Owners of Parent
45.9 44.4 26.6 2015
56.9 61.0 (Up 7.1%) 62.0 54.3 36.2 60.5 (Up 11.3%)
40.5 39.5 2016
(Fiscal years to March 31)
(Japanese standards)
18/25
(Up 9.1%)
2017
(Forecast)
2017
(Forecast)
(IFRS)
Financial Targets:
Sales and Operating Income by Region
Net Sales
56.4 60
38.5 4
30
20
2.4 *
2.4 *
10
3.5 *
*
2
2.0 *
2016
2017
(Fiscal years to March 31)
Net Sales
60
40
36.2 20
4.1
*
2015
5.5
*
5.4
*
2016
2017
(Fiscal years to March 31)
Net Sales
20
*
5.6 *
2017
IFRS
Operating Income
*
*
2015
10
2
5
0
0
140
122.9 6
120
2017
2017
IFRS
22.6 113.6 31.1
43.5
*
113.6
60
17.8 79.5
*
20
62.0
40
1.4
2.8
3.1
3.5
3.5
10
2
14.7 40
30
20.1
Operating
Income
22.6 3
50
101.0 80
Operating Income
AP
41.7
*
43.9
*
103.8
2
20.0 15
144.0
*
(Fiscal years to March 31)
20
160
‐2
2016
Net Sales
25
(Billions of yen)
Operating
Income
60
159.6 159.6
Japan
Net Sales
100
*
Net Sales
4
7.1
2.7
0
Operating Income
0
2014
6.4
5.1
2014
6
6.8 *
8.6 30
2017
IFRS
Operating
China
Income
10
74.1 74.1 65.1 8
49.8 Net Sales
80
14
10
53.1 10
0
2015
63.2 73.3 73.3 68.4 50
40
3.5 0
2014
80
60
Operating
Income
EMEA
Net Sales
70
47.0 50
40
Operating
Income
59.0 59.0 6
Americas
20
1.3
*
1.8
*
1.8 1.3
1.2
1
0
2015
2016
2017
(Fiscal years to March 31)
Net Sales
19/25
40.3
2017
IFRS
Operating Income
40.5
39.8
42.5
42.5
0
2014
*
2014
0
2015
2016
2017
2017
IFRS
(Fiscal years to March 31)
Intra-Area Transfers: Exports to Group Affiliates, Others
Sales to Customers: IDEXX and Others
Sales to Customers: Japan
Operating Income
*Revision in intragroup transaction prices
Consolidated Earnings Forecast for the
Fiscal Year Ending March 31, 2017
(Billions of yen)
Japanese
Standard
IFRS
Difference
Net Sales
275.0
275.0
±0
Cost of Sales
112.5
114.0
+1.5
Gross Profit
162.5
161.0
-1.5
101.5
99.0
-2.5
Operating Income
61.0
62.0
+1.0
Income before
Income Taxes
60.2
61.5
+1.3
Profit Attributable to
Owners of Parent
39.5
40.5
+1.0
SG&A Expenses
20/25
Main Reasons for Differences
Increase in amortization expenses due to
capitalization of research expenses: +¥1.7 billion
Capitalization of research expenses: -¥2.3 billion
Non-amortization of goodwill: -¥1.0 billion
Actuarial differences on retirement benefits: +¥0.5
billion
Other non-operating items, etc.: +¥0.3 billion
Dividend Increases for the 15th Consecutive Fiscal Year
(Forecast for the Year Ending March 31, 2017)
Sysmex aims to maintain a proper balance between aggressive investment, which is
designed to sustain steady high growth, and returns to our shareholders as our earning
power increases. In terms of returns to shareholders, we intend to provide a stable dividend
on a continuous basis and aim for a consolidated payout ratio of 30% under our basic policy
of sharing the successes of our operations in line with business performance.
Notes: Two-for-one stock split conducted on November 18, 2005
Two-for-one stock split conducted on April 1, 2011
Two-for-one stock split conducted on April 1, 2014
(Yen)
60
Dividend (annual) retroactively converted to basis following stock
split on April 1, 2014
52
54
50
Dividend payout ratio (consolidated)
38
40
27
30
12.5
20
18.9%
22.6%
5
6.5
2005
2006
9
15
17
2011
2012
20
12 31.9% 14
29.4% 27.0% 29.1% 29.1% 27.1% 29.6% 29.8% 27.7%
26.8%
17.8% 17.9% 20.0%
10
3.125 3.75
0
2003
2004
2007
2008
2009
2010
(Fiscal years to March 31)
21/25
2013
2014
2015 2016 2017
(Proposal) (Forecast)
Reference Information
(Reference) Financial Results for the
Fiscal Year Ended March 31, 2016
(Billions of yen)
IFRS*
Japanese
(Reference Difference
Standard
Value)
Main Reasons for Differences
Net Sales
253.1
253.1
±0
Cost of Sales
102.0
102.3
+3
Gross Profit
151.0
150.8
△3
SG&A Expenses
94.1
90.0
△41
Capitalization of research expenses: -¥2.35 billion
Non-amortization of goodwill: - ¥1.93 billion
Operating Income
56.9
60.8
+38
Includes non-operating items, etc., of +¥0.01 billion
Income before
Income Taxes
54.6
57.9
+32
Marginal difference on revision of retirement benefit
plan: -¥0.55 billion
Profit Attributable to
Owners of Parent
36.2
38.8
+25
Increase due to capitalization of research expenses:
+¥0.44 billion
* Results for the fiscal year ended March 31, 2016 (IFRS) are provided as reference values and take into account
only major effects.
23/25
(Reference) Comparison with IFRS
Fiscal Year Ended
March 31, 2016 *
(Reference Value)
Fiscal Year Ending
March 31, 2017
(Billions of yen)
Difference
Net Sales
253.1
275.0
+21.9
Cost of Sales
102.3
114.0
+11.7
Gross Profit
150.8
161.0
+10.2
SG&A Expenses
90.0
99.0
+9.0
Operating Income
60.8
62.0
+1.2
Income before
Income Taxes
57.9
61.5
+3.6
Profit Attributable to
Owners of Parent
38.8
40.5
+1.7
* Results for the fiscal year ended March 31, 2016 (IFRS) are provided as reference values and
take into account only major effects.
Actual exchange rates Assumed exchange
for the fiscal year ended rates for the fiscal year
March 31, 2016
ending March 31, 2017
1USD
¥120.1
¥110.0
1EUR
¥132.6
¥125.0
1CNY
¥18.9
¥17.0
24/25
(Reference) Differences between IFRS and
Japanese Standard
Fiscal Year
Ended March
31, 2016
(Reference
Value)
Net Sales
Cost of Sales
Gross Profit
0
(Billions of yen)
Fiscal Year
Ending March
31, 2017
Main Reasons for Differences
0
+0.3
+1.5
-0.3
-1.5
SG&A
Expenses
-4.1
-2.5
Operating
Income
+3.8
+1.0
25/25
Increase arising from differences in
amortization expenses due to the capitalization
of research expenses: +¥1.30 billion
Decrease stemming differences due to nonamortization of goodwill: +¥0.80 billion
Marginal profit due to revision of retirement
benefit plan: +¥0.47 billion (fiscal year ended
March 31, 2016)
Contact:
IR & Corporate Communication Dept.
Corporate Communication Div.
Phone: +81-78-265-0500
Email: [email protected]
www.sysmex.co.jp/en